Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Thalidomide with or without dexamethasone for refractory multiple myeloma].

M Boulin1, F Blanchet, N Isambert

  • 1Service Pharmacie, C.H.U. Bocage, Boulevard Maréchal De Lattre De Tassigny, Dijon, France. mathbouw@yahoo.fr

Therapie
|April 2, 2003
PubMed
Summary

Thalidomide showed a 33% response rate in refractory multiple myeloma patients. Combining thalidomide with dexamethasone yielded a higher response rate, suggesting further study for this multiple myeloma treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Experimental evaluation of survival of Vibrio parahaemolyticus in fertilized cold-water sediment.

Journal of applied microbiology·2020
Same author

Radiolabeled F(ab')<sub>2</sub>-cetuximab for theranostic purposes in colorectal and skin tumor-bearing mice models.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2018
Same author

MANOTA: a promising bifunctional chelating agent for copper-64 immunoPET.

Dalton transactions (Cambridge, England : 2003)·2017
Same author

Minor changes in the macrocyclic ligands but major consequences on the efficiency of gold nanoparticles designed for radiosensitization.

Nanoscale·2016
Same author

Impact of pharmaceutical intervention on quality of life and coping strategies in patients with haematological malignancies.

Annales pharmaceutiques francaises·2016
Same author

[Can one harvest a long bone stick in the radial forearm flap? Original radioanatomical and NanoSPECT-CT Bioscan microvascular study].

Annales de chirurgie plastique et esthetique·2014

Area of Science:

  • Hematology
  • Clinical Oncology
  • Pharmacology

Context:

  • Refractory multiple myeloma presents a significant clinical challenge with limited treatment options.
  • Thalidomide emerged as a potential therapeutic agent for multiple myeloma in 1999.
  • Previous studies indicated thalidomide's efficacy in patients resistant to standard therapies.

Purpose:

  • To evaluate the efficacy and safety of thalidomide monotherapy in patients with refractory multiple myeloma.
  • To assess the response rate and progression-free survival of thalidomide treatment.
  • To explore the potential benefit of combining thalidomide with dexamethasone in this patient population.

Summary:

  • Twenty-one patients with refractory multiple myeloma received thalidomide at 400 mg/day, achieving a 33% response rate and 15-month median progression-free survival.

Related Experiment Videos

  • Common side effects included drowsiness and constipation, with five patients developing peripheral neuropathy.
  • Eight patients received combination therapy with thalidomide and dexamethasone (with or without chemotherapy), resulting in a high response rate.

    • Impact:

    • The findings suggest that thalidomide is an active agent in refractory multiple myeloma.
    • Combination therapy with thalidomide and dexamethasone appears promising and warrants further investigation.
    • A prospective, randomized trial comparing thalidomide/dexamethasone combination to thalidomide monotherapy is recommended for optimal refractory multiple myeloma treatment.